Personalis (PSNL) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free PSNL Stock Alerts $1.43 +0.03 (+2.16%) (As of 12:12 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 4:05 PM | businesswire.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 13, 2024 | americanbankingnews.comPersonalis, Inc. (NASDAQ:PSNL) to Post Q3 2024 Earnings of ($0.29) Per Share, HC Wainwright ForecastsMay 13, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Personalis (NASDAQ:PSNL)May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amid Strong Financial Performance and Strategic Growth ProspectsMay 9, 2024 | markets.businessinsider.com4 Analysts Have This To Say About PersonalisMay 9, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comPersonalis First Quarter 2024 Earnings: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comIs Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?May 9, 2024 | marketbeat.comPersonalis' (PSNL) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $3.50 price target on shares of Personalis in a research note on Thursday.May 9, 2024 | finance.yahoo.comPersonalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...May 8, 2024 | investorplace.comPSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comPersonalis Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comPersonalis is about to announce its earnings — here's what to expectMay 2, 2024 | msn.comLake Street Initiates Coverage of Personalis (PSNL) with Buy RecommendationMay 1, 2024 | marketbeat.comPersonalis (PSNL) to Release Quarterly Earnings on WednesdayPersonalis (NASDAQ:PSNL) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=589017)April 30, 2024 | marketbeat.comLake Street Capital Begins Coverage on Personalis (NASDAQ:PSNL)Lake Street Capital assumed coverage on Personalis in a research report on Tuesday. They set a "buy" rating and a $4.00 target price for the company.April 24, 2024 | businesswire.comPersonalis to Announce First Quarter 2024 Financial ResultsApril 11, 2024 | marketbeat.comPersonalis (NASDAQ:PSNL) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $3.50 price objective on shares of Personalis in a research report on Thursday.April 2, 2024 | investing.comCathie Wood's ARK makes major moves in Tesla stock, sells RobinhoodMarch 29, 2024 | investing.comCathie Wood's ARK buys over $14M in Tesla stock, sells Coinbase in latest tradesMarch 28, 2024 | businesswire.comPersonalis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | businesswire.comData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 27, 2024 | marketbeat.comARK Investment Management LLC Increases Stock Position in Personalis, Inc. (NASDAQ:PSNL)ARK Investment Management LLC increased its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 16.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,671,545 shares of the company's stock afteMarch 26, 2024 | finance.yahoo.comPersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response MonitoringMarch 19, 2024 | businesswire.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | finance.yahoo.comPSNL Apr 2024 2.500 putMarch 6, 2024 | finance.yahoo.comPSNL Apr 2024 7.500 callMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed: Personalis’s Strategic Advances and Financial Health Signal Promising Growth in 2024March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amidst Strategic Partnerships and Revenue Growth ProspectsMarch 1, 2024 | seekingalpha.comPersonalis, Inc. (PSNL) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | uk.finance.yahoo.comPersonalis, Inc. (PSNL)February 29, 2024 | finance.yahoo.comPersonalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketbeat.comNeedham & Company LLC Boosts Personalis (NASDAQ:PSNL) Price Target to $3.50Needham & Company LLC raised their price target on Personalis from $2.30 to $3.50 and gave the stock a "buy" rating in a research report on Thursday.February 28, 2024 | benzinga.comPersonalis: Q4 Earnings InsightsFebruary 28, 2024 | finance.yahoo.comPersonalis Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | markets.businessinsider.comWhat Wall Street expects from Personalis's earningsFebruary 14, 2024 | finance.yahoo.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | businesswire.comPersonalis to Announce Fourth Quarter and Full Year 2023 Financial ResultsJanuary 31, 2024 | finance.yahoo.comPersonalis to Participate at Upcoming Investor ConferencesJanuary 30, 2024 | markets.businessinsider.comPersonalis, ClearNote Health Join Hands To Advance Epigenomic TechnologyJanuary 30, 2024 | finance.yahoo.comPersonalis and ClearNote Health Announce Partnership to Advance Epigenomic TechnologyJanuary 22, 2024 | finance.yahoo.comPersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 16, 2024 | finance.yahoo.comPersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling AssayJanuary 7, 2024 | uk.investing.comPersonalis reports 18% Q4 revenue growth, eyes 2026 runwayJanuary 6, 2024 | markets.businessinsider.comBuy Rating for Personalis Amid Strong Growth and Promising VA MVP DevelopmentsJanuary 5, 2024 | markets.businessinsider.comPersonalis Expects Q4 Revenue To Grow 18%January 5, 2024 | marketbeat.comPersonalis' (PSNL) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $2.30 price target on shares of Personalis in a research report on Friday.January 3, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Personalis (PSNL)December 18, 2023 | finance.yahoo.comEven With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance CompletelyDecember 4, 2023 | finance.yahoo.comPersonalis Extends Cash Position Into 2026, Provides Update on Key Initiatives Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Email Address "The Biggest Drug Ever" Is Coming (Ad)UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. Get the name of the stock here >>> PSNL Media Mentions By Week PSNL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSNL News Sentiment▼0.760.42▲Average Medical News Sentiment PSNL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSNL Articles This Week▼31▲PSNL Articles Average Week Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ENZ News Today XGN News Today DMTK News Today BDSX News Today SERA News Today SLS News Today CGTX News Today TKNO News Today VTVT News Today AFMD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSNL) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold"The Biggest Drug Ever" Is ComingBehind the MarketsMost important medical advance in 100 yearsThe Oxford ClubDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.